Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)


Link M. S., Giugliano R. P., Ruff C. T., Scirica B. M., Huikuri H., Oto A., ...More

CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, vol.10, no.1, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1161/circep.116.004267
  • Journal Name: CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: atrial fibrillation, bleeding, mortality, stroke, thromboembolism, ASSOCIATION TASK-FORCE, AMERICAN-COLLEGE, WARFARIN, MANAGEMENT, COLLABORATION, PERSISTENT, GUIDELINES, EDOXABAN, UPDATE
  • Gazi University Affiliated: Yes

Abstract

Background-Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of anticoagulation is controversial. In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality. However, detailed analyses by AF pattern have not been reported.